by RIVANNA | May 7, 2026 | Press Releases
CHARLOTTESVILLE, VA – MAY 7, 2026 – RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Accuro® XV Diagnostic Ultrasound System. The clearance...
by RIVANNA | May 5, 2026 | Press Releases
Nomination places the Charlottesville-based company among growth-stage medtech leaders recognized for commercial momentum in AI-powered clinical decision support; public voting is open through May 8. CHARLOTTESVILLE, VA, May 5, 2026 — RIVANNA®, developer of AI-powered...
by RIVANNA | Apr 29, 2026 | Press Releases
CHARLOTTESVILLE, VA, APRIL 29, 2026 — RIVANNA®, developer of AI-powered clinical decision-support solutions, recently published the findings of a study demonstrating that the novel, automated musculoskeletal imaging system Accuro® XV can produce diagnostic images of...
by RIVANNA | Apr 21, 2026 | Press Releases
Company accelerates AI-enabled fracture detection development, compressing anticipated FDA 510(k) timeline CHARLOTTESVILLE, VA, APRIL 22, 2026 — RIVANNA®, developer of AI-enabled clinical decision-support solutions, announced that it has expanded its clinical studies...
by RIVANNA | Apr 21, 2026 | News
Neuraxial anesthesia remains a foundational component of modern anesthetic practice, supporting procedures ranging from labor analgesia to major surgical interventions. In 2026, the field continues to evolve under the combined influence of clinical complexity,...
